



(12) Translation of
European patent specification

(11) NO/EP 3366295 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/675 (2006.01)
A61K 31/53 (2006.01)
A61K 31/6615 (2006.01)
A61K 31/665 (2006.01)
A61K 31/683 (2006.01)
A61K 31/685 (2006.01)
A61P 31/14 (2006.01)
C07D 487/04 (2006.01)
C07D 519/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.06.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.01.22
(86)	European Application Nr.	18167340.1
(86)	European Filing Date	2015.10.29
(87)	The European Application's Publication Date	2018.08.29
(30)	Priority	2014.10.29, US, 201462072331 P 2015.01.20, US, 201562105619 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3212174, 2015.10.29
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	CHUN, Byoung, Kwon, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA CLARKE, Michael, O'Neil Hanrahan, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA DOERFFLER, Edward, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA HUI, Hon, Chung, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA JORDAN, Robert, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA MACKMAN, Richard, L., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA PARRISH, Jay, P., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA RAY, Adrian, S., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA 94404, USA

SIEGEL, Dustin, c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA
94404, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS**

(56) References

Cited:

US-A1- 2010 015 094


WO-A1-2012/012776


AESOP CHO ET AL: "Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 8, 1 April 2012 (2012-04-01), pages 2705-2707, XP55238769, AMSTERDAM, NL ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2012.02.105

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse valgt fra gruppen bestående av:





eller et farmasøytisk akseptabelt salt derav.

2. Farmasøytisk sammensetning som omfatter en terapeutisk effektiv mengde
 5 av forbindelsen ifølge krav 1
 eller et farmasøytisk akseptabelt salt derav.

3. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, og minst et ytterligere terapeutisk middel.
4. Farmasøytisk sammensetning ifølge krav 3, hvor det minst ene ytterligere terapeutiske midlet er valgt fra gruppen bestående av ribavirin, palivizumab, motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, amiodaron, dronedaron, verapamil, Ebola rekonvalesent plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroksymetyl)pyrrolidin-3,4-diol), favipiravir (også kjent som T-705 eller Avigan), T-705 monofosfat, T-705 difosfat, T-705 trifosfat, FGI-106 (1-N,7-N-bis[3-(dimetylamino)propyl]-3,9-dimetylkinolino[8,7-h]kinolon-1,7-diamin), JK-05, TKM-Ebola, ZMapp, rNAPc2, VRC-EBOADC076-00-VP, OS-2966, MVA-BN filo, brincidofovir, Vaxart adenovirusvektor 5-basert ebolavaksine, Ad26-ZEBOV, FiloVax vaksine, GOVX-E301, GOVX-E302, ebola virusinhibitorer (NPC1-inhibitorer), og rVSV-EBOV, og blandinger derav.
5. Farmasøytisk sammensetning ifølge krav 4, hvor det minst ene ytterligere terapeutiske midlet er ZMapp.
6. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for å behandle en *Filoviridae*-virusinfeksjon hos et menneske.
7. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for å behandle en ebolavirusinfeksjon hos et menneske.
8. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for å behandle en Marburg-virusinfeksjon hos et menneske.